672 related articles for article (PubMed ID: 32017978)
1. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
2. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
3. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
4. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
5. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
6. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
7. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
8. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
9. An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions.
Lewis V; Rurak G; Salmaso N; Aguilar-Valles A
Trends Neurosci; 2024 Mar; 47(3):195-208. PubMed ID: 38220554
[TBL] [Abstract][Full Text] [Related]
10. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
12. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
[TBL] [Abstract][Full Text] [Related]
13. Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.
Cardona-Acosta AM; Bolaños-Guzmán CA
Neuropharmacology; 2023 Mar; 225():109374. PubMed ID: 36516891
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
15. The rapid-onset antidepressant effect of ketamine: More surprises?
Raffa RB; Pergolizzi JV; Taylor R;
J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
[TBL] [Abstract][Full Text] [Related]
16. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
17. Ketamine: Leading us into the future for development of antidepressants.
Carreno FR; Lodge DJ; Frazer A
Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
[TBL] [Abstract][Full Text] [Related]
18. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Maeng S; Zarate CA; Du J; Schloesser RJ; McCammon J; Chen G; Manji HK
Biol Psychiatry; 2008 Feb; 63(4):349-52. PubMed ID: 17643398
[TBL] [Abstract][Full Text] [Related]
19. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
